anastrozole has been researched along with Carcinoma, Ovarian Epithelial in 5 studies
Carcinoma, Ovarian Epithelial: A malignant neoplasm that originates in cells on the surface EPITHELIUM of the ovary and is the most common form of ovarian cancer. There are five histologic subtypes: papillary serous, endometrioid, mucinous, clear cell, and transitional cell. Mutations in BRCA1, OPCML, PRKN, PIK3CA, AKT1, CTNNB1, RRAS2, and CDH1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A subset of patients with estrogen- or progesterone-positive platinum-resistant or platinum-refractory recurrent epithelial ovarian cancers derives clinical benefit from anastrozole, with acceptable toxicity." | 5.24 | Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer. ( Beale, PJ; Bonaventura, A; DeFazio, A; Friedlander, ML; Goh, JCH; Grant, PT; Hadley, AM; Mapagu, C; Martyn, J; McNally, OM; Mileshkin, LR; OʼConnell, RL; Scurry, J; Sjoquist, KM, 2017) |
| "Anastrozole was well-tolerated." | 2.90 | PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; Davis, A; deFazio, A; Friedlander, M; Goh, J; Grant, P; Kennedy, CJ; McNally, O; Mileshkin, L; Moujaber, T; O'Connell, RL; Scurry, J; Sjoquist, KM; Sykes, P; Tan, K; Tang, M, 2019) |
| "Anastrozole was well tolerated." | 2.90 | PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. ( Amant, F; Antill, Y; Beale, P; Bonaventura, T; DeFazio, A; Friedlander, M; Goh, J; Grant, P; Kok, PS; Mapagu, C; O'Connell, RL; Scurry, J; Sjoquist, K, 2019) |
| "After confirming the diagnosis of ovarian cancer with a laparoscopic biopsy, neoadjuvant chemotherapy was scheduled." | 1.72 | [Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report]. ( Fukino, S; Hamasaki, T; Kodama, W; Nishimura, K; Oota, R; Suo, K; Takagi, Y; Tanaka, Y, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tanaka, Y | 3 |
| Oota, R | 3 |
| Takagi, Y | 3 |
| Kodama, W | 3 |
| Nishimura, K | 3 |
| Hamasaki, T | 3 |
| Fukino, S | 3 |
| Suo, K | 3 |
| Bonaventura, A | 1 |
| OʼConnell, RL | 1 |
| Mapagu, C | 2 |
| Beale, PJ | 1 |
| McNally, OM | 1 |
| Mileshkin, LR | 1 |
| Grant, PT | 1 |
| Hadley, AM | 1 |
| Goh, JCH | 1 |
| Sjoquist, KM | 2 |
| Martyn, J | 1 |
| DeFazio, A | 3 |
| Scurry, J | 3 |
| Friedlander, ML | 1 |
| Tang, M | 1 |
| O'Connell, RL | 2 |
| Amant, F | 2 |
| Beale, P | 2 |
| McNally, O | 1 |
| Grant, P | 2 |
| Davis, A | 1 |
| Sykes, P | 1 |
| Mileshkin, L | 1 |
| Moujaber, T | 1 |
| Kennedy, CJ | 1 |
| Tan, K | 1 |
| Antill, Y | 2 |
| Goh, J | 2 |
| Bonaventura, T | 2 |
| Friedlander, M | 2 |
| Kok, PS | 1 |
| Sjoquist, K | 1 |
| Esfahani, K | 1 |
| Ferrario, C | 1 |
| Le, P | 1 |
| Panasci, L | 1 |
3 trials available for anastrozole and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epi | 2017 |
PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Cystadenoc | 2019 |
PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; CA- | 2019 |
2 other studies available for anastrozole and Carcinoma, Ovarian Epithelial
| Article | Year |
|---|---|
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
[Breast and Advanced Ovarian Double Cancer with a BRCA2 Pathogenic Variant-A Case Report].
Topics: Anastrozole; BRCA2 Protein; Breast; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Female; Humans; | 2022 |
Aromatase inhibition in relapsing low malignant potential serous tumours of the ovary.
Topics: Adult; Anastrozole; Antineoplastic Agents, Hormonal; Carcinoma, Ovarian Epithelial; Female; Humans; | 2014 |